Amgen’s MariTide Delivers 20% Weight Loss in Phase 2 and Advances to 72-Week Phase 3 Trial

Amgen plans a 72-week pivotal study following phase 2 results that showed substantial weight loss alongside lower gastrointestinal side effects from a low-dose ramp-up.